Once-Weekly Semaglutide in Adults with Overweight or Obesity

Abstract

To the Editor: The risk of hypoglycemia in patients who are receiving glucagon-like peptide-1 (GLP-1) analogues as monotherapy is considered to be insignificant. In the recent phase 3 Semaglutide Treatment Effect in People with Obesity 1 (STEP 1) trial by Wilding et al. (March 18 issue),¹ the incidence of hypoglycemia that was associated with the GLP-1 analogue semaglutide was only 0.6% in adults with overweight or obesity. However, in a similar trial of another GLP-1 analogue (liraglutide),² investigators found a higher incidence of hypoglycemia with liraglutide than with placebo (11.9% vs. 3.3%). In that trial, the majority of cases of . . .